The EVERY Company, a leading biotechnology innovator specializing in precision fermentation-based proteins, announced it has raised $55 million in Series D financing to accelerate its nationwide rollout and strengthen its position in the $270 billion global egg market. The funding round was led by McWin Capital Partners, through the McWin Food Tech Fund, with participation from Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, New Agrarian, SOSV, and other investors.
The new capital will be used to expand manufacturing capacity, advance the company toward profitability, and drive mass-market adoption of its animal-free egg proteins across retail and foodservice channels. EVERY’s ingredients, including its flagship OvoPro and OvoBoost, are already commercialized online and in foodservice applications, with major distribution to begin this month through Walmart stores across the United States.
The company’s expansion comes as food producers grapple with volatile egg prices and fragile supply chains driven by avian flu outbreaks, supply shortages, and rising feed costs. EVERY’s precision fermentation technology provides a stable, cage-free-compliant alternative to traditional eggs, delivering equivalent or superior functionality while eliminating exposure to livestock-related risks.
EVERY’s proteins are shelf-stable for up to 18 months and available in powder form, enabling efficient logistics and eliminating cold chain costs for bakery and food manufacturers. The company has achieved consistent commercial-scale output, producing metric tons of product each month. It aims to meet the demand of some of the world’s largest food companies through its expanding manufacturing network.
Backed by McWin Capital Partners, a private equity and venture capital firm focused on food technology and sustainability, EVERY’s progress signals a maturing biomanufacturing sector capable of supporting the next generation of food production.
EVERY, headquartered in San Francisco, develops precision-fermented egg proteins for use across bakery, beverage, and packaged food applications. Its products, OvoPro and OvoBoost, are FDA-approved and designed to replace conventional egg and egg white functionality or enhance protein fortification in food and drink formulations.
KEY QUOTES:
“This new injection of capital will allow us to make good on our promise of making products that are accessible to everyone – in every state, every city, and every grocery store. This milestone first close is a powerful validation of our ambitions and we’re grateful for the trust of our incredible investors.”
“If the last two years have taught us anything, it’s that our current food system remains incredibly fragile. One outbreak can wipe out hundreds of millions of hens. For food companies small and large, that kind of risk just isn’t tenable – and we now have the answer.”
Arturo Elizondo, Co-Founder and CEO of EVERY
“EVERY has crossed the line from promise to proof. They’re not talking about proof-of-concept pilots here – they’re selling metric tons of product at scale to some of the biggest food companies on the planet. EVERY is exactly the type of platform that will define the next decade of food production.”
Martin Davalos, Partner & Head of Food Tech at McWin Capital Partners
“EVERY is proving what this technology can do — real products solving real customer problems, at industrial scale, with a clear path to profitability. Their progress shows how biomanufacturing has matured into a resilient, scalable part of the global food supply chain. This is a massive opportunity to build the next generation of food production.”
Phil Morle, Partner at Main Sequence
